Capsular contracture is a highly distressing, difficult complication after breast augmentation for both the patient and the surgeon. Although capsular contracture is a multifactorial process, one common denominator in the successful treatment of this complication is believed to be the abatement of inflammation. Leukotriene antagonists have recently emerged as effective prophylactic agents in reactive airway diseases. Anecdotal reports have indicated that zafirlukast (Accolate, AstraZeneca) effectively reverses capsular contracture. A prospective study of capsular contracture in 120 female patients in whom a total of 216 prostheses were implanted was performed. The hardness of capsular contracture was assessed by means of the mammary compliance method (Anton Paar Mammacompliance system). The patients were divided into two groups: patients in group A received zafirlukast for a 6-month period, while those in group B received vitamin E. The results show a significant decrease of the values of breast compliance after 6 months in group A but not in group B and that the variation in compliance after 6 months in group A compared to group B is statistically significant. In zafirlukast-treated patients, we observed a reduction in mammary compliance of 7.69% after 1 month, 16.78% after 3 months and 24.01% after 6 months. The present study suggests that zafirlukast may be effective in reducing pain and breast capsule distortion in patients with longstanding contracture who are either not surgical candidates or who do not wish to undergo surgery. Capsular contracture is the most common problem and cause of patient dissatisfaction following augmentation mammaplasty and mammary reconstruction with breast implants; the reported rates of this complication range from 0.5 to 30% (1-2).
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Every patient who undergoes implantation with an alloplastic implant experiences capsules around the prostheses. Breast firmness that is so marked that it results in a painful, hard breast, occasionally with visible distortion, has been termed fibrous capsular contracture (3) (4) (5) . A number of intra-operative and post-operative factors may be linked to capsular contracture. Unfortunately, as few strictly-controlled studies have been conducted to investigate the causes and possible prevention ofcapsular contracture, there are as yet no definite data on the aetiopathogenesis of this complication (4) (5) .
A number of treatments designed to reverse capsular contracture have also been proposed and used, all with varying success. These treatments may be either surgical (i.e. capsulotomy or capsulectomy in which the implant can be replaced or the plane of placement changed) or pharmacological (such as delayed intracapsular instillation of steroids and antibiotics), though the success rate of these also varies (6) .
The causes of capsular contracture have not yet been fully understood. There are two major theories, one ofwhich is based on a non-infectious mechanism and the other on an infectious mechanism (3). Myofibroblast populations arise during the active phase of wound healing and eventually disappear in the mature phase (3) .
Experimental evidence has demonstrated that following implantation of a silicone prosthesis, a foreign-body reaction ensues and the host tissues wall off or encapsulate the implant. Identification of myofibroblasts in contracted and non-contracted capsules alike suggests that all capsules contract to some degree. Within this biologic milieu, extrinsic factors, including the biophysical and biochemical properties of the implant, infection and hematoma, may potentiate or exaggerate the foreign-body reaction and result in the pathologic condition we recognize clinically as capsular contracture. To date, unfortunately, the etiological factors in the formation of capsular contracture, which are likely to be multiple, remain unclear in spite of an extensive body of research (7) (8) .
Although the process causing capsular contracture appears to be multifactorial, one common denominator in its successful treatment may be the abatement of inflammation. The triggering of inflammation, and in some cases of the development of. capsular contracture, begins with the normal healing process. It is possible that the fluid retained around the breast implant following surgery causes ongoing inflammation. Pharmacological inhibition of the inflammatory process has, indeed, now become the main focus of research (7-10).
Leukotriene antagonists have recently emerged as effective prophylactic agents in reactive airway diseases (11-12). Anecdotal reports, and subsequent clinical trials, have indicated that zafirlukast (Accolate'?", AstraZeneca Pharmaceuticals, Wilmington De, USA) and montelukast (Singulair'>', Merk Sharp & Dohme, Whitehouse Station, New Jersey, USA) effectively reverse capsular contracture following breast augmentation, reportedly because of their inhibition of cysteinyl leukotrienes (LTC 4 LTD 4 , and LTE 4 ) and their presumed suppressive effect on myofibroblasts, two factors presumed to cause contracture (13) (14) (15) (16) (17) .
In November 1996, the Food and Drug Administration approved the use of zafirlukast, a leukotriene receptor antagonist (LTRA), for the treatment of asthma. This class of drugs has the unique ability to prevent asthma symptoms, which is preferable to treating the attack once it occurs. In vitro studies have demonstrated that zafirlukast inhibits the eosinophilic influx and contractile activity of smooth muscle in all 3 leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in both humans and laboratory animals. Moreover, studies have shown that in sheep, zafirlukast also suppresses the eosinophilic response, thereby reducing bronchial "hyper-responsiveness" (18) (19) . Since November 1996, zafirlukast has been prescribed millions of times. It is indicated for the preventive and long-term treatment of asthma in adults and children of 12 years of age or older. It is generally well tolerated, though it does have possible side effects that include headache (12.9%), nausea (3.1%) and, extremely rarely, liver disease. A series of coincidences contributed to the discovery of zafirlukast's effects on capsular contracture (20) .
In literature, there are no controlled studies on the effects of zafirlukast on capsular contracture by means of an objective system, all the previous studies having used a subjective measurement of· capsular contracture. The most accurate means of objectively assessing the hardness of the breast after the placement of an implant is the measurement of mammary compliance using the Anton Paar Mammacompliance system (Polytech Europe Dieburg Germany) (21) (22) (23) .
All the work is performed by a computer that develops both a numerical value and a diagram of the compliance showing the hardness of the breast.
This system has been found to be effective in eliminating the descriptive part and in keeping to the measurements and objective data; moreover, this system is easily reproducible during check-ups and provides an objective assessment of capsular contracture (22) (23) .
The purpose of this study is to evaluate the effect of zafirlukast on mammary compliance in a series of patients in whom breast prostheses were implanted and who developed capsular contracture.
MATERIALS AND METHODS
A prospective study was planned. We enrolled 120 consecutive female patients with mild to severe capsular contracture in at least one breast in whom 216 prostheses had been implanted from September 2004 to October 2005. (Tab. I). We excluded patients with liver, kidney or lung disease, patients with chronic disease of the skin (psoriasis, sclerodermitis), patients who were pregnant and patients over 55 years of age. The age of the patients ranged from 23 to 55 years (mean: 38 years and 6 months; median: 33 years). The time elapsed since the prosthesis implantation ranged from 7 months to 3 years and 5 months (mean: I year and 4 months, median: I year and I month).
In 106 cases, the implant was an anatomic implant filled with cohesive silicone gel, in 58 cases the implant was a round double lumen implant filled with silicone gel and saline solution, while in the remaining 52 cases the implant was a round implant filled with silicone gel. The size of the implants ranged from 165 to 440 grams for the anatomic implants, from 200 to 400 cc for the round double lumen implants and from 175 to 375 cc. for the round implants filled with silicone gel. All the double lumen implants were filled with the recommended amount of saline solution. All the implants had a textured shell.
All the patients were informed of the possible risks associated with the off-label use of zafirlukast.
Once they had given their informed consent, the patients were enrolled in the study. All the patients underwent regular liver function tests; no changes in liver function were observed. Each patient was randomly assigned into two groups: A and B.
Patients in group A received zafirlukast (Accolatet'") 20 mg PO BID for a 6-month period. Because of the welldocumented adverse effects of this agent, which include liver failure and hepatitis, patients were offered hepatic profiles at 0, 3, and 6 months after beginning the regimen, as well as the option to terminate the study at any time.
Patients in group B received vitamin E 400 IU orally twice daily for 6 months.
Breasts were assessed at the start ofthe study (TO),each month (Tl, T2, T3, T4, and T5) as well as at the end of the study (T6) by means ofthe Anton Paar Mammacompliance system by one operator. Capsular contracture scores thus obtained for each affected breast at each time point were compared with those from the other time points. The operators did not know which grot p the patient was from, nor were any of the operators aware of the result of any of the other measurements. 95% Confidence intervals (CI) of the means of TO, Tl, T2, T3, T4, T5 and T6 values in both groups were calculated and plotted. TOand T6 values in each group were compared using Student's t test for paired groups. Then the differences among TO and T6 values in each implanted breast were compared between group A and B using Student's T test for independent groups.
RESULTS
The mean value and standard deviations (SO) of mammary compliance in each group obtained at the different time points are summarized in Table II .
The 95% CI of the mean values at different times shows that at TO the two groups have overlapping means whereas during treatment the two groups diverge, being group B values higher than group A (Fig. I) Moreover, the values for each implanted breast at T6 is significantly lower than TO values in group A (P<O.OI), whereas the difference is not statistically significant in group B (Tab. III). The comparison of the differences in TO-T6 values between group A and group B is statistically highly significant (P<O.OI) (Tab. IV).
We did not observe any major complications, only one patient presented hypertension during the study but we decided to continue the experimentation. None of the other patients had any untoward effects of the drug during the course of the regimen.
All the hepatic profiles carried out on the patients during the course of the study were normal.
DISCUSSION
Although we do not completely understand the cause of capsular contracture after breast augmentation or reconstruction, an exaggerated inflammatory response does occur. The role of specific cells such as the macrophage or mast cell, while yet to be fully elucidated, is supported by previous studies. It may be possible to modify the leukotriene receptor antagonists (LTRAs) so as to alter the inflammatory cascade just enough to prevent the severe fibrotic reaction that is associated with capsular contracture (15) .
However, a more targeted approach that focuses on limiting the inflammatory response may yield better results. Leukotriene receptor antagonists (LTRAs) have proved to be both effective and safe in the treatment of asthma. Their anti-inflammatory characteristics target early cellular-mediated proliferation without producing generalized immuno- suppression.
The role of the macrophage and the mast cell may be particularly important in the physiological mechanisms by which leukotriene receptor antagonists (LTRAs) inhibit capsular contracture. It has been suggested that myofibroblasts are the cause of excess collagen production and extracellular matrix deposition since they share the properties of both fibroblasts and smooth muscle cells (9-10, [24] [25] [26] [27] . In addition, in 1981 Baker et al. specifically indicated the myofibroblast as being the probable cause of capsular contracture, postulating that drugs that inhibit myofibroblast smooth muscle activity would be beneficial in preventing capsular contracture (7) .
If the myofibroblast is indeed responsible for the exaggerated collagen deposition and the resultant smooth muscle activity postulated in capsular contracture, immunomodulation at the cellular level may be able to reduce capsular contracture. These mechanisms include inhibition of the macrophage and mast cell response. Firstly, by reducing the cellular response of SRS-A (substance of anaphylaxis), the "histamine-like" response generated by eosinophills, mast cells, neutrophils and lymphocytes would be inhibited. Secondly, by preventing monocyte activation, cytokine and growth factor release as well as the production of superoxide radicals, the inflammatory cascade would be significantly reduced (19, (28) (29) .
A report by Niessen et al. suggests that the macrophage is a pivotal intermediary between the inflammatory phase and scar formation. The macrophage release of fibroblast activating cytokines, which transforms growth factor-B, platelet-derived growth facter-and interleukins, is important in collagen production, organization, and extracellular matrix degradation (24) . Niessen et al. suggest that all cellular and immunological processes, not fibroblast activity alone, lead to the formation of excessive scar tissue. There may also be a relationship between mast cells and scars, as is suggested by the fact that mast cells are found in dermal collagen bundles as well as in higher numbers in hypertrophic scars than in 'normal' scars. The mast cell response is characterized by histaminelike activity, which is capable of stimulating collagen formation and is notably increased in keloid tissue. The result is an increase in the collagen matrix found in scar tissue. This response is directly inhibited by LTRAs and appears to reduce the rate of capsular contracture (14, 24) . Although it is generally accepted that the macrophage and mast cell play an important role in wound healing, their precise role in the formation of capsular contracture is not fully understood. We believe that both myofibroblast smooth muscle contractility and prolonged collagen deposition may be involved in the development of capsular contracture. If so, reducing the activity of the macrophage and mast cell may prove useful. Use of LTRAs to diminish the early inflammatory process induced, in large part, by the macrophage and mast cell may indeed impede further cellular mechanisms, such as myofibroblast activity, fibroblast proliferation and collagen deposition. The mechanism by which zafirlukast reduces or prevents capsular contracture is not yet completely clear and deserves further investigation (13) (14) (15) (16) .
Our results in this pilot study show a favorable response to the treatment ofcapsular contracture with zafirlukast in a group of patients who had undergone breast implant surgery and taken zafirlukast for 6 months (group A). Plotting the means with the 95% CI at TO, Tl T2, T3, T4, T5, T6 of the two groups we note that at TO they are very close and the intervals overlap, indicating an homogeneity of the studied population and a progressive divergence of the intervals, being lower in group A, suggesting a possible effect of zafirlukast. A significant reduction of breast compliance in group A was shown and the decrease of compliance after 6 months in group A is significantly higher than in group B. Moreover, we observed that the treated breasts responded either completely or partially to the leukotriene antagonist. We observed a reduction in mammary compliance in these patients of 7.69% after 1 month, 16.78% after When evaluating mammary compliance, great importance is attributed to graphs because they may show the severity of capsular contracture. Curvilinear graphs indicate mild capsular contracture, whereas rectilinear graphs indicate severe capsular contracture. In our study, the graphs reveal a remarkable improvement in the breasts after the use of zafirlukast ( Fig. 2a-b) .
It is noteworthy that the higher the mammary compliance value, the greater the reduction in capsular contracture after one month of zafirlukast therapy. Another noteworthy point is that the reduction in mammary compliance value is positively correlated with the time elapsed since the development of capsular contracture -the shorter the time, the greater the reduction.
We also observed a decrease in the mammary compliance values in the breast that did not present capsular contracture, though this reduction was less marked than that observed in the breast with capsular contracture.
Our data seem to indicate that neither the use of vitamin E nor breast massage and implant movement markedly reduce capsular contracture.
Although these results support the use of zafirlukast in this setting, studies designed to assess the long-term effects of this drug are warranted. In patients with longstanding contracture who are neither surgical candidates nor wish to undergo surgery, zafirlukast may however effectively reduce both pain-and the distortion of the breast capsule (13) (14) . The use of zafirlukast needs a careful monitoring as normal doses have been reported to cause liver failure in a very small number of patients, most of whom were women who presented anorexia, right upper quadrant pain, pruritus and jaundice. Two of these patients eventually underwent orthotopic liver transplants. The onset of hepatocellular dysfunction ranged from 2 to 18 months (30).
In conclusion, we have found that zafirlukast is highly effective on established capsular contracture, though the precise mechanism by which the leukotriene receptor antagonists (LTRAs) decrease or prevent capsular contracture is not yet fully understood. In addition , longer follow-up studies are warranted to determine the long-term effects of Accolate on capsular contracture prevention and treatment. Lastly, further studies should be designed to investigate how long the effects of zafirlukast last after the patient has been taken off therapy. Fig. 2a, b . Mammary comp liance graphs from the sam e patient before (a) and after six months ofzafi rlukast therapy (b) measured using the Anton Paar Mammacompliance system. This device measures the distance between two sensors on application ofa known f orce. The measurement starts at a base value of0.5 and ends when a value ofover 15 New tons (N) is reached. The diameter ofthe breast is measured when fo rces ofO.5 Nand 15 N are applied. These measurements are then used to calculate the mammary compliance according to the f ollowingformula: D15 = «,*100% /d o {%]. D15 is the mammary compliance and diSand dorepresent the mamm ary diameter measured in millim eters with respective fo rces of 15 and 0.5 Newtons (N). Each breast is measured in eight diff erent positions and the arithmetic mean ofthe various measurements calculated. The grap h show that, after treatment,f rom low to high values offo rce we observe wider range ofdistance, indicating higher comp liance ofthe implanted breast.
